Anti-S100A9 and anti-TNFα treatment significantly reduced the maximum arthritis score median, from 6.8 in the isotype control-treated group to 3 and 1.4 in groups treated with anti-S100A9 and anti-TNFα, respectively (Fig. 2D). The gene discussed is S100A9; the disease is arthritic joint disease.